Long-Term Follow-Up Of A Phase 1, Firstin-Human Open-Label Study Of Lcar-B38m, A Structurally Differentiated Chimeric Antigen Receptor T (Car-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma), In Patients (Pts) With Relapsed/Refractory Multiple Myeloma (Rrmm)